Vaccine patents

Subscribe to updates on this page: Vaccine RSS

Date/App#	List of recent Vaccine-related patents
12/05/13 20130324590	Production and utilization of a novel anti-cancer drug in therapy This invention generally relates to a design and method for developing novel anti-tumor and/or anti-cancer drugs, vaccines and therapies, using microrna and/or its shrna homologues/mimics/derivatives. More specifically, the present invention relates to an use of a prokaryote-produced mirna precursor (pro-mirna) composition capable of being delivered into human cells and processed by the cells into mature mirna effectors to elicit specific silencing effects on mir-302-targeted genes, subsequently leading to a beneficial result of tumor suppression and cancer therapy.
12/05/13 20130323832	Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance The present invention is based on the discovery antigen-presenting cells (apcs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (ido). Because expression of high levels of ido is correlated with a reduced ability to stimulate t cell responses and an enhanced ability to induce immunologic tolerance, apcs having high levels of ido may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders.
12/05/13 20130323821	Non-natural amino acid replication-dependent microorganisms and vaccines Compositions and methods of producing vaccines, including methods wherein whole organism vaccines are provided with limited replication abilities, thereby increasing vaccine safety and efficacy, through the use of non-natural, unnatural, or non-naturally encoded amino acids.. .
12/05/13 20130323278	Chimeric flavivirus vaccines A chimeric live, infectious, attenuated virus containing a yellow fever virus, in which the nucleotide sequence for a prm-e protein is either deleted, truncated, or mutated, so that functional prm-e protein is not expressed, and integrated into the genome of the yellow fever virus, a nucleotide sequence encoding a prm-e protein of a second, different flavivirus, so that the prm-e protein of the second flavivirus is expressed.. .
12/05/13 20130323277	Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof The present invention relates to the field of vaccines and medicaments for the prophylaxis and treatment of infectious diseases in ruminants. In particular, it relates to inactivated schmallenberg virus (sbv) useful as vaccine or medicament for preventing or treating viremia, the transmission and clinical symptoms, in particular malformations in newborn ruminants such as cattle, sheep and goats, induced by sbv..
12/05/13 20130323276	Malaria vaccines based on pre-erythrocytic antigens from p. falciparum The present invention relates to polypeptides or fragments thereof for use as malaria vaccines. It also relates to nucleic acid molecules coding for the polypeptides of the invention.
12/05/13 20130323210	Infectious schmallenberg virus from cloned cdnas and uses thereof The present invention belongs to the field of animal health and relates to a nucleic acid sequence which comprises the complete genome of an infectious schmallenberg virus (sbv) useful for studying viremia and diseases caused by sbv in ruminants, and in the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of viremia and diseases caused by sbv.. .
11/28/13 20130315959	Compounds The invention provides a synthetic c. Difficile ps-ii cell wall saccharide.
11/28/13 20130315958	Pneumococcal serotypes Disclosed is a new and emerging serotype of streptococcus pneumoniae designated serotype 6c, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {2) glucose 1 (1→3) glucose 2 (1→3) rhamnose (1→3) ribitol (5→phosphate}.
11/28/13 20130315956	Newcastle disease virus and the use thereof as a vaccine The present invention relates to a new newcastle disease viruses of any genotype and novel fragments of the newcastle disease virus genome encoding for the f and hn proteins constructed by reverse genetics and recombination, highly antigenic, for preparing vaccines for the prevention of the newcastle disease by reducing viral shedding or for using as vectors with other viruses, lyophilized or in oil emulsion. Likewise, it can be used as vector in combination with other pathogenic agents..
11/28/13 20130315954	Method for improving the production of influenza viruses and vaccine seeds The present invention relates to a method for improving the production of an influenza virus, and in particular influenza vaccine seeds, or a vaccine directed against an influenza virus, characterized in that the production is carried out in the presence of an inhibitor of the interaction between the mdm2 protein and the p53 protein.. .
11/28/13 20130315950	Methods and compositions using listeria for adjuvant treatment of cancer Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen.
11/28/13 20130315949	Molecular antigen array The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array.
11/28/13 20130315947	Vaccination of animals to elicit a protective immune response against tick infestations and tick-borne pathogen transmission Two antigenic and immunogenic proteins of the cattle tick, rhipicephalus microplus, and the genes encoding these proteins, are effective for eliciting a protective immune response that controls and prevents infestations of bovines and other livestock by the tick. The proteins isolated from the cattle tick include an aquaporin protein and a tc5777 gut membrane protein.
11/28/13 20130315945	Yeast-based vaccines as immunotherapy Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed..
11/28/13 20130315942	Wdrpuh epitope peptides and vaccines containing the same The present invention provides peptides containing the amino acid sequence of seq id nos: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic t cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides.
11/28/13 20130315916	Respiratory syncytial virus vaccine Described is a vaccine against respiratory syncytial virus (rsv). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the rsv-encoded small hydrophobic (sh) protein.
11/28/13 20130315857	Kexin-derived vaccines to prevent or treat fungal infections A vaccine is disclosed that promotes cd4+ t cell-independent host defense mechanisms to defend against infection by fungi such as pneumocystis spp. The vaccine may be used to prevent or to treat fungal infections.
11/21/13 20130309273	Thermostable vaccine compositions and methods of preparing same The disclosure provides compositions relating to thermostable vaccines and methods of preparing same. Specifically, the disclosure provides for methods of preparing thermostable vaccines based on a recombinant ricin neurotoxin protein and uses of co-adjuvants to develop a composition capable of eliciting an immune response in a subject..
11/21/13 20130309271	Method for producing a vaccine for the treatment of cancer The present invention discloses a method for producing a haptenized vaccine from a tissue biopsy. The method includes obtaining a tissue biopsy, isolating the cells, irradiating the cells, haptenizing the cells, and cryopreserving the cells.
11/21/13 20130309270	Vaccines comprising bisphosphonate and methods of use thereof The present invention demonstrates that bisphosphonates have an intrinsic adjuvant activity and directly stimulate b cell antibody secretion. Accordingly, the present invention provides vaccines comprising a bisphosphonate, methods for stimulating an immune response, enhancing the immunogenicicty of an immunogen, and methods of treating an infection, an autoimmune disease, an allergy, and/or a cancer using the same..
11/21/13 20130309269	Methods for producing yeast-based vaccines The invention provides methods for culturing yeast at a neutral ph level. Yeast cultured under neutral ph conditions exhibit desirable characteristics useful for biological purposes, such as the development of vaccines, prophylactics and therapeutics.
11/21/13 20130309265	Yeast-based therapeutic for chronic hepatitis c infection Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis c virus (hcv) and for treating or preventing hepatitis c viral infection in an animal. The invention includes a variety of novel hcv fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against hcv in an animal.
11/21/13 20130309263	Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning The invention provides isolated polynucleotide molecules that comprise a dna sequence encoding an infectious rna sequence encoding a genetically-modified north american prrs virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided..
11/21/13 20130309262	Hsv-1 epitopes and methods for using same The invention provides hsv antigens and epitopes that are useful for the prevention and treatment of hsv infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with hsv.
11/21/13 20130309261	Hypoallergenic polypeptides for the treatment of house dust mite allergy The present invention relates to a polypeptide comprising the amino acid sequence as shown in seq id no:9 or 7. The invention further pertains to nucleic acids encoding the polypeptide, pharmaceutical compositions and vaccines..
11/21/13 20130309260	Human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1 Novel muc-1 epitopes outside the vntr region are identified. In addition, the first agonist epitope of muc-1 is described.
11/21/13 20130309259	Wdhd1 peptides and vaccines including the same Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from seq id no: 32, that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) are provided.
11/21/13 20130309193	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated t-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses.
11/14/13 20130302373	Attenuated mycoplasma gallisepticum strains The present invention provides live, attenuated mycoplasma gallisepticum bacteria that exhibit reduced expression of a protein identified as mga_0621. In certain embodiments, the attenuated bacteria may additionally exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein l35, relative to a wild-type m.
11/14/13 20130302371	Immunogenic respiratory syncytial virus glycoprotein-containing vlps and related compositions, constructs, and therapeutic methods The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (vlps) which are useful in the treatment and prevention of respiratory syncytial virus (rsv) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g.
11/14/13 20130302368	Advanced prime and boost vaccine This invention relates to vaccines and in particular to the combination of non-integrating, replication-incompetent retroviral vectors (niv) with virus-like particle (vlp) vaccines to induce an immune response in an animal host following administration to the host. This combination results in a novel vaccine strategy for delivering priming and boost doses, wherein an effective amount of an niv is administered to the host, followed by an effective amount of a vlp.
11/14/13 20130302367	Virus vector for prime/boost vaccines, which comprises vaccinia virus vector and sendai virus vector Provided is a set of virus vectors for prime/boost vaccines, comprising the following virus vector (a) and virus vector (b): (a) a vaccinia virus vector which carries a gene encoding an immunogenic polypeptide in such a manner that the gene can be expressed; and (b) a sendal virus vector which carries the gene encoding the immunogenic polypeptide in such a manner that the gene can be expressed.. .
11/14/13 20130302364	Highly immunogenic hiv p24 sequences The invention relates to peptides comprising part or all of a conserved element within a center-of-tree (cot) sequence derived from a family of polypeptides encoded by naturally occurring variants of hiv. The invention also relates to immunogenic compositions and vaccines comprising said peptides.
11/14/13 20130302361	Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including psa, psma, steap and psca antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens psa, psma, steap and psca, as well genetic constructs/vectors and vaccines expressing the sequences.
11/07/13 20130296382	Non-nucleoside reverse transcriptase inhibitors Are hiv reverse transcriptase inhibitors, wherein r1, r2, r3, r4 and r5 are defined herein. The compounds of formula i and their pharmaceutically acceptable salts are useful in the inhibition of hiv reverse transcriptase, the prophylaxis and treatment of infection by hiv and in the prophylaxis, delay in the onset or progression, and treatment of aids.
11/07/13 20130295139	Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is gap-dmorie..
11/07/13 20130295136	Live attenuated catfish vaccine and method of making A high throughput bioluminescence mutant screening procedure is disclosed. This procedure utilizes robotics, and bacterial luciferase to allow real-time monitoring of mutant viability.
11/07/13 20130295135	Functional influenza virus like particles (vlps) The present invention discloses and claims virus like particles (vlps) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising vlps of the inventions.
11/07/13 20130295128	Chimeric vaccines The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein.
11/07/13 20130295126	Vaccines for inclusion body hepatitis A composition comprising an isolated fowl adenovirus (fadv), wherein the fadv is a strain selected from fadv-2, fadv-7, fadv-8a, fadv-8b, fadv-8a/8b or fadv-11 serotype strains; and a suitable carrier and methods for inducing protective immunity in a subject and/or its progeny.. .
11/07/13 20130295120	Vaccines based on targeting antigen to dcir expressed on antigen-presenting cells The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a dcir-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.. .
11/07/13 20130295046	Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or immunostimulant..
11/07/13 20130295043	Vaccination in elderly patients The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit..

@FreshPatents